Abstract
To the Editor:In a recent study in this Journal, Drummond and colleagues (5) attempt to address the question “Whether the standard methods of HTA are adequate for assisting decisions on patient access to and funding of orphan drugs” before proposing “a research agenda to help understand the societal value of orphan drugs and issues surrounding their development, funding, and use.”
Publisher
Cambridge University Press (CUP)
Reference17 articles.
1. McCabe C , Claxton K , Tsuchiya A .2005 Orphan drugs and the NHS: Should we value rarity?BMJ.31:1016–1019.
2. NICE.2004.Imatinib for unresectable and/or metastatic gastro-intestinal tumours: Technology Appraisal 86.London:NICE;October
3. Drummond MF , Wilson DA , Kanavos P , Ubel P , Rovira J .2007 Assessing the economic challenges posed by orphan drugs.Int J Technol Assess Health Care.23:36–42.
4. Griffin S , Claxton K , Palmer S , Sculpher MJ .2007 Dangerous omissions: The consequences of ignoring decision uncertainty.Med Decis Making.27:E8.
5. McCabe C , Tsuchiya A , Claxton K , Raftery J .2006 Orphan drugs revisited.Q J Med.99:341–345.
Cited by
17 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献